Beyond Cellular Therapies: The Expanding Role of Antibody-Driven Immunotherapy in Pediatric Acute Lymphoblastic Leukemia
David McCall(The University of Texas MD Anderson Cancer Center), Branko Cuglievan(The University of Texas MD Anderson Cancer Center), Priti Tewari(The University of Texas MD Anderson Cancer Center), Ramya Ramakrishnan(The University of Texas MD Anderson Cancer Center), Miriam B. Garcia(The University of Texas MD Anderson Cancer Center), Amber Gibson(The University of Texas MD Anderson Cancer Center), Samanta Catueno(The University of Texas MD Anderson Cancer Center), César Núnêz(The University of Texas MD Anderson Cancer Center), Irtiza Sheikh(The University of Texas MD Anderson Cancer Center)
Cited by 3
Related Papers
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy
|Nature Reviews Clinical Oncology|2018|237
Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: an international expert position statement
|The Lancet Haematology|2019|83
Pediatric Aggressive Mature B-Cell Lymphomas, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|67
Venetoclax for Children and Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
|Cancers|2021|66
Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer
|Nature Reviews Clinical Oncology|2021|59